2025-12-24 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data provided, broken down into sections as requested.

**1. Return Rate Comparison:**

*   **Overview:** Johnson & Johnson (JNJ) is a multinational corporation that manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **Cumulative Return (JNJ):** 59.05%
*   **Cumulative Return (VOO/S&P 500):** 100.88%
*   **Divergence:** -41.8%
*   **Relative Divergence:** 28.9%

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The divergence of -41.8% shows a substantial difference in cumulative returns. The relative divergence of 28.9% suggests that the current divergence is closer to the minimum observed in the past, indicating a period of greater underperformance compared to its historical fluctuations.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 335.7 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.0 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 350.4 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 378.1 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 411.0 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 424.4 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 376.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 347.4 |
| 2023-2025  | 30.0% | 79.6% | -35.0% | 0.1 | 495.8 |

**Analysis:**

*   **CAGR:** Fluctuates significantly, ranging from negative returns to positive 30%.
*   **MDD (Maximum Drawdown):** Consistently high, indicating substantial risk exposure.
*   **Alpha:** Mostly negative, especially in recent periods (2019-2025), suggesting JNJ is underperforming relative to its benchmark. The 2020-2022 period shows positive Alpha, indicating outperformance.
*   **Beta:** Relatively low, indicating lower volatility compared to the market.
*   **Cap(B):** Market capitalization shows growth over time but reflects recent declines.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 206.37
*   **Last Market Data:** Price: 205.78, Previous Close: 207.32, Change: -0.74
*   **5-day SMA:** 209.70
*   **20-day SMA:** 206.46
*   **60-day SMA:** 195.83

**Analysis:** The current price is below the 5-day SMA and around the 20-day SMA, but above the 60-day SMA. This suggests a potential short-term downtrend, but the price is still supported by the longer-term 60-day SMA. The negative change in the last market data (-0.74) reflects a recent downward move.

**3. RSI, PPO, and Divergence Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 53.23 (Neutral)
*   **PPO:** -0.19 (Slightly Bearish)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent Divergence Change:** -5.1% (Short-term Decline)
*   **Expected Return (%):** -59.0%

**Analysis:**

*   **MRI:** Suggests a medium investment recommendation, implying moderate risk.
*   **RSI:** At 53.23, the RSI is neutral, not indicating overbought or oversold conditions.
*   **PPO:** The negative PPO indicates that the short-term moving average is below the long-term moving average, a slightly bearish signal.
*   **Hybrid Signal:** The signal recommends buying with a high allocation, suggesting confidence despite other indicators.
*   **Recent Divergence Change:** Indicates a short-term decline in relative performance.
*   **Expected Return:** The negative expected return suggests caution, projecting underperformance relative to the S&P 500 over a longer period.

**4. Recent News & Significant Events:**

*   **Talc Litigation:** Multiple headlines focus on talc-related lawsuits, including a significant $1.5 billion payment order. These lawsuits create negative sentiment and uncertainty around the stock.
*   **Analyst Targets:** Articles mention analyst targets and what to watch for in 2026.
*   **Market Performance:** Articles note that the stock dropped despite market gains and that it is trading above its 50-day and 200-day SMAs.
*   **Surging Shares:** One article suggests a reason for the surge in J&J shares this month.

**Analysis:** Recent news is a mixed bag. While some articles point to positive technical indicators (trading above SMAs) and potential reasons for short-term surges, the talc litigation is a significant overhang, potentially driving down the stock price and contributing to negative sentiment.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~2.16)
*   **Target Price:** 209.29 (avg) / 240.00 (high) / 155.00 (low)

**Analysis:** Despite recent underperformance and legal challenges, the analyst consensus is to "Buy." The average target price is slightly above the current price, suggesting a modest potential upside. However, the wide range between the high and low target prices reflects uncertainty and differing opinions.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.30 | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

**Analysis:** Earnings per share (EPS) and revenue figures have fluctuated over the past few quarters. The most recent EPS is 2.14, and revenue is $23.99B. The EPS varies considerably, with a high of 4.57. The revenue shows some variability but remains relatively stable.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $23.99B    | 69.56%        |
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-09-30   | $79.28B    | 6.50%    |
| 2025-06-30   | $78.47B    | 7.06%    |
| 2025-03-31   | $78.11B    | 14.08%   |
| 2024-12-31   | $71.49B    | 4.80%    |
| 2024-09-30   | $70.16B    | 3.84%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been relatively stable, with a slight increase in the most recent quarter. Profit margins are consistently high, indicating strong operational efficiency.
*   **Capital and Profitability:** Equity has grown steadily over the past year. Return on Equity (ROE) has fluctuated, with a significant spike in 2025-03-31.

**7. Comprehensive Analysis (Summary):**

Johnson & Johnson (JNJ) is currently facing a mixed outlook.

*   **Underperformance:** JNJ has underperformed the S&P 500 significantly over the analyzed period. This is reflected in the large negative divergence.
*   **Talc Litigation:** The ongoing talc litigation represents a substantial risk and is likely contributing to negative market sentiment.
*   **Mixed Signals:** Technical indicators provide mixed signals. The price is near the 20-day SMA, but above the 60-day SMA, which indicates a short-term downtrend. RSI is neutral, while PPO is slightly bearish.
*   **Analyst Optimism:** Analysts, on average, maintain a "Buy" rating with a slightly higher target price. However, this optimism needs to be weighed against the risks.
*   **Financial Strength:** JNJ remains a financially strong company with stable revenue, high profit margins, and growing equity.

**Conclusion:**

Based on this data, caution is warranted. While JNJ possesses financial strength and analyst support, the underperformance compared to the market and the legal challenges should be carefully considered. The mixed technical signals and negative expected return further suggest the need for a cautious approach. Potential investors should weigh these factors against their risk tolerance and investment horizon.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.